Compare Stocks → The #1 Biotech Stock to Have on Your Radar in 2024… (From Huge Alerts) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACSTNASDAQ:CLSNNASDAQ:GANXNASDAQ:IMRA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$2.94+2.1%$3.33$1.72▼$3.84$27.63M1.4926,275 shs8,422 shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsGANXGain Therapeutics$3.19-5.9%$4.04$2.00▼$5.65$51.74M0.43154,201 shs146,812 shsIMRAIMARA$17.12$0.97▼$6.32$165.80M1.09138,364 shs271,700 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma+1.05%-14.54%-15.29%+19.50%+0.13%CLSNImunon0.00%0.00%0.00%0.00%0.00%GANXGain Therapeutics+6.94%+7.28%-16.50%+3.67%-32.47%IMRAIMARA0.00%0.00%0.00%0.00%0.00%The #1 Biotech Stock to Have on Your Radar in 2024… (Ad)Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!Learn more about why Zack’s has a BULLISH nearly $19 price target on BSEM right now!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACSTAcasti Pharma2.5315 of 5 stars3.55.00.00.00.60.81.3CLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AGANXGain Therapeutics3.5704 of 5 stars3.55.00.00.03.92.50.6IMRAIMARAN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma3.00Buy$6.00104.08% UpsideCLSNImunonN/AN/AN/AN/AGANXGain Therapeutics3.00Buy$8.50166.46% UpsideIMRAIMARAN/AN/AN/AN/ACurrent Analyst RatingsLatest ACST, GANX, IMRA, and CLSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024GANXGain TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.004/1/2024GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/27/2024GANXGain TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/7/2024ACSTAcasti PharmaCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti PharmaN/AN/AN/AN/A$9.14 per shareN/ACLSNImunon$500K0.00N/AN/A$9.66 per share0.00GANXGain Therapeutics$50K1,034.84N/AN/A$0.97 per share3.29IMRAIMARAN/AN/AN/A75.24$3.44 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-$42.43M-$5.08N/AN/AN/AN/A-13.18%-11.32%6/28/2024 (Estimated)CLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AGANXGain Therapeutics-$22.27M-$1.71N/AN/AN/AN/A-193.03%-123.21%5/10/2024 (Estimated)IMRAIMARA$1.49M$0.05126.40N/AN/AN/A2.12%2.00%N/ALatest ACST, GANX, IMRA, and CLSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023GANXGain Therapeutics-$0.32-$0.29+$0.03-$0.29N/AN/A2/12/202412/31/2023ACSTAcasti Pharma-$0.23-$0.21+$0.02-$0.21N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AIMRAIMARAN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A15.1915.19CLSNImunon0.136.526.52GANXGain Therapeutics0.043.593.59IMRAIMARAN/A48.9848.98OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma6.08%CLSNImunon12.97%GANXGain Therapeutics11.97%IMRAIMARA49.28%Insider OwnershipCompanyInsider OwnershipACSTAcasti Pharma13.51%CLSNImunon4.66%GANXGain Therapeutics11.00%IMRAIMARA37.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma329.40 million8.13 millionNot OptionableCLSNImunon277.10 million6.77 millionOptionableGANXGain Therapeutics2816.22 million14.44 millionOptionableIMRAIMARA4126.23 million16.45 millionNot OptionableACST, GANX, IMRA, and CLSN HeadlinesSourceHeadlinePapa Francis aendesha misa ya Alhamisi akiwa imaradw.com - April 14 at 8:16 PMAt Ira Khan-Nupur Shikhare's Wedding, Imran Khan Spotted With His Daughter Imarandtv.com - January 6 at 1:21 PMImara Blumehealth.usnews.com - August 23 at 6:28 AMRioZim : Change of Directors & Management - Marketscreener.comnews.google.com - May 12 at 10:59 PMEnliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results - Yahoo Financenews.google.com - May 12 at 2:56 AMLufa rolls our School Fee Subsidy Program - Papua New Guinea ... - PNG Factsnews.google.com - May 11 at 11:54 AMFletcher, Hunte Claim MEAC Player And Pitcher Of The Year Honors ... - Morgan State Bearsnews.google.com - May 11 at 11:54 AMMore than 300 Lufa students receive K2 million - POST-COURIERnews.google.com - May 10 at 7:20 PMIn Conversation With JUNO Women's Aid: "This Work Is Much Needed" - Impact Magazinenews.google.com - May 10 at 9:18 AMLocal elections: town and parish council results in Bracknell - Bracknell Newsnews.google.com - May 10 at 9:18 AMMEAC Announces 2023 Softball Academic Honors - Morgan State ... - Morgan State Bearsnews.google.com - May 10 at 4:18 AMKenya's CMA urges reinstatement of preferential tax rates - The East Africannews.google.com - May 9 at 8:16 AM2023 NIDA Production Season - AussieTheatre.comnews.google.com - May 9 at 3:16 AM5 ways to explore your gender identity : Life Kit - NPRnews.google.com - May 8 at 5:15 PM47 Top-Scoring Plants to Check Out for Your 2023 Garden, From ... - Lancaster Farmingnews.google.com - May 6 at 9:21 AMFast fashion is over: it's time for sustainable Irish designers - Irish Examinernews.google.com - May 6 at 12:32 AMWeird worlds: the most extreme exoplanets we've discovered - Interesting Engineeringnews.google.com - May 5 at 7:32 PM10 fashion designers putting Ireland on the map - RTE.ienews.google.com - May 5 at 8:40 AM47 top-scoring plants to check out for your 2023 garden, from ... - LNP | LancasterOnlinenews.google.com - May 5 at 8:40 AMGymnastics: Acrobay enjoy Scottish NDP Championships success - Dunfermline Pressnews.google.com - May 3 at 2:35 PMI&M Bank increases loan limit to Sh10mn - Capital FM Kenyanews.google.com - May 3 at 9:27 AMIsland Revelers is Best Troupe, Brandon Joseph Best Individual in ... - The Daily Heraldnews.google.com - May 3 at 1:05 AMAzimio protests marred by chaos again - Nairobi - Kenya Broadcasting Corporationnews.google.com - May 2 at 10:03 AMLIVE BLOG: Raila Resumes Mass Protests After Bipartisan Talks Fail - Kenyans.co.kenews.google.com - May 2 at 5:02 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcasti PharmaNASDAQ:ACSTAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Gain TherapeuticsNASDAQ:GANXGain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies. The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds. It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.IMARANASDAQ:IMRAIMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.